|
gptkbp:instanceOf
|
gptkb:drug
long-acting beta2-adrenergic agonist
|
|
gptkbp:approvedBy
|
1998
|
|
gptkbp:ATCCode
|
gptkb:R03AC13
|
|
gptkbp:bioavailability
|
43-90%
|
|
gptkbp:brand
|
gptkb:Foradil
Oxis
|
|
gptkbp:CASNumber
|
73573-87-2
|
|
gptkbp:chemicalClass
|
gptkb:phenylethanolamine
|
|
gptkbp:combines
|
gptkb:budesonide
gptkb:beclometasone
gptkb:mometasone
glycopyrronium
|
|
gptkbp:contraindication
|
hypersensitivity to formoterol
tachyarrhythmia
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
|
|
gptkbp:eliminationHalfLife
|
10 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:has_stereochemistry
|
arformoterol
|
|
gptkbp:hasMolecularFormula
|
C19H24N2O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Formoterol
|
|
gptkbp:IUPACName
|
N-[2-hydroxy-5-[(1RS,2SR)-2-hydroxy-5-(hydroxymethyl)-1-methyl-1-phenylpropyl]phenyl]formamide
|
|
gptkbp:KEGGID
|
D04022
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
beta2-adrenergic receptor agonist
|
|
gptkbp:MeSH_ID
|
D020253
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
344.4 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
61-64%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201313
3083540
DB00983
|
|
gptkbp:routeOfAdministration
|
inhalation
|
|
gptkbp:sideEffect
|
headache
tremor
palpitations
muscle cramps
|
|
gptkbp:synonym
|
Eformoterol
Formoterol fumarate
|
|
gptkbp:UNII
|
935E97BOY8
|
|
gptkbp:usedFor
|
asthma
chronic obstructive pulmonary disease
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Zentiva
|
|
gptkbp:bfsLayer
|
7
|